SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma - Quaterly Results

26 May 2025 Evaluate
The sales slipped to Rs. 27319.90 millions for the March 2025 quarter as against Rs. 28940.30 millions during the year-ago period.The Net Profit of the company registered a slight decline of -29.46% to Rs. 4081.70  millions from Rs. 5786.70 millions.Operating Profit reported a sharp decline to 7104.90 millions from 8977.60 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 27319.90 28940.30 -5.60 109333.00 106456.40 2.70 109333.00 106456.40 2.70
Other Income 1139.80 1229.70 -7.31 3281.20 6160.60 -46.74 3281.20 6160.60 -46.74
PBIDT 7104.90 8977.60 -20.86 28856.90 28401.00 1.61 28856.90 28401.00 1.61
Interest 610.90 530.70 15.11 2300.40 1826.00 25.98 2300.40 1826.00 25.98
PBDT 6494.00 8446.90 -23.12 26556.50 26575.00 -0.07 26556.50 26575.00 -0.07
Depreciation 938.80 648.10 44.85 2972.00 2545.80 16.74 2972.00 2545.80 16.74
PBT 5555.20 7798.80 -28.77 23584.50 24029.20 -1.85 23584.50 24029.20 -1.85
TAX 1473.50 2012.10 -26.77 6116.60 5028.20 21.65 6116.60 5028.20 21.65
Deferred Tax -79.00 -64.50 22.48 -157.10 -952.60 -83.51 -157.10 -952.60 -83.51
PAT 4081.70 5786.70 -29.46 17467.90 19001.00 -8.07 17467.90 19001.00 -8.07
Equity 580.80 585.90 -0.87 580.80 585.90 -0.87 580.80 585.90 -0.87
PBIDTM(%) 26.01 31.02 -16.17 26.39 26.68 -1.07 26.39 26.68 -1.07

Aurobindo Pharma Share Price

1385.65 -0.45 (-0.03%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×